Complete institutional exit by a meaningful backer, significant underperformance (down 15.4% over past year and 42.07 percentage points below S&P 500), and characterization as 'beaten-down' indicate deteriorating investor confidence and poor stock performance.
Articles that tag HRMY but are mainly about other companies.
Biopharmaceutical company focused on rare neurological disorders with limited competition and higher pricing power. Lead drug WAKIX recently expanded for pediatric use. Attractive regulatory advantages and alignment with precision medicine trend.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
